ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
-0.49%
US Dollar vs MXN
16.564
0.05%
Brent Oil
83.125
-0.48%
Bitcoin
70,986.65
-0.65%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vanda Pharmaceuticals Inc (VNDA)

  7. Vanda Pharmaceuticals Inc (VNDA) Noticias

VNDA Vanda Pharmaceuticals Inc

5.30
-0.18 (-3.28%)
20 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Vanda Pharmaceuticals Inc VNDA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.18 -3.28% 5.30 17:00:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
5.39 5.26 5.475 5.27 5.48
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
20/5/202416:26EDGAR2Form 8-K - Current report
15/5/202407:45PRNUSVanda Pharmaceuticals Reports Positive Results from a Second..
13/5/202415:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
09/5/202416:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
09/5/202406:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202415:06EDGAR2Form 8-K - Current report
08/5/202415:01PRNUSVanda Pharmaceuticals Reports First Quarter 2024 Financial..
07/5/202415:51EDGAR2Form 8-K - Current report
07/5/202410:16PRNUSVanda Pharmaceuticals Confirms Receipt of Revised..
30/4/202415:30PRNUSVanda Pharmaceuticals to Announce First Quarter 2024..
25/4/202407:05GLOBEShareholder Capital Delivers Letter to Independent Members..
22/4/202418:13PRNUSVanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial..
17/4/202409:21PRNUSVanda Pharmaceuticals Adopts Limited Duration Stockholder..
17/4/202408:02PRNUSVanda Pharmaceuticals Confirms Rejection of Unsolicited..
03/4/202409:25APSBiotech Catches Major Premarket Bid Following FDA Approval
02/4/202417:10PRNUSVanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S...
07/3/202415:31EDGAR2Form 8-K - Current report
06/3/202415:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202415:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202415:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202415:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202406:00PRNUSVanda Pharmaceuticals Announces FDA Update for supplemental..
04/3/202420:14EDGAR2Form 144 - Report of proposed sale of securities
04/3/202420:12EDGAR2Form 144 - Report of proposed sale of securities
04/3/202420:10EDGAR2Form 144 - Report of proposed sale of securities
04/3/202420:08EDGAR2Form 144 - Report of proposed sale of securities
04/3/202420:06EDGAR2Form 144 - Report of proposed sale of securities
21/2/202415:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:32EDGAR2Form 8-K - Current report
16/2/202415:31EDGAR2Form 8-K/A - Current report: [Amend]
08/2/202406:19EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07/2/202415:07EDGAR2Form 8-K - Current report
07/2/202415:02PRNUSVanda Pharmaceuticals Reports Fourth Quarter and Full Year..
05/2/202415:34EDGAR2Form 8-K - Current report
05/2/202407:00PRNUSVanda Pharmaceuticals Announces FDA Update for supplemental..
31/1/202415:30PRNUSVanda Pharmaceuticals to Announce Fourth Quarter and Full..
31/1/202408:00PRNUSVanda Pharmaceuticals Receives FDA Approval to Proceed with..
30/1/202411:35PRNUSCourt Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag..
29/1/202418:00PRNUSCourt Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag..
25/1/202421:05PRNUSVanda Pharmaceuticals Announces a U.S. Patent Allowance for..
25/1/202412:07PRNUSVanda Pharmaceuticals announces the publication of an..
23/1/202410:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23/1/202408:15PRNUSVanda Pharmaceuticals Receives FDA Approval to Proceed with..
19/1/202415:57DJNVanda Pharma's Trade Secrets Suit Against FDA Moves Forward
19/1/202414:56PRNUSFederal Court Allows Vanda Pharmaceuticals' Lawsuit to..

Su Consulta Reciente

NASDAQ
VNDA
Vanda Pharmaceuticals
BIT
P1DD61
BNP Paribas Issuance
NASDAQ
STRC
Palladyne AI
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados